Delivery Order 36F79721D0068-36C26024F0319
Award Date
4/1/24
Potential Completion Date
5/10/24
Potential Value
Not listed
Federal Agency
Veterans Integrated Service Network 20
Awardee
Urogen Pharma Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
La Vergne, TN 37086, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs (VA) awarded a firm-fixed-price delivery order to Urogen Pharma Inc., a for-profit pharmaceutical company, to provide the drug JELMYTO. The order, valued at $98,856.06, is being placed under the VA's Pharmaceuticals and Drugs Federal Supply Schedule contract. JELMYTO is used to treat low-grade upper tract urothelial cancer in veterans. This order is one of several federal contracts Urogen Pharma holds with the VA to supply JELMYTO, including a $2.5 million...
This is a federal contract award by the Department of Veterans Affairs (VA) to Urogen Pharma Inc., a for-profit pharmaceutical company, for the supply of JELMYTO KIT - ANTINEOPLASTIC ANTIBIOTICS. The contract has a ceiling value of $102,264.12 and an ultimate completion date of September 30, 2025. The contract is structured as a Delivery Order under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is priced on a Firm Fixed Price basis. This contract award is not designated...
This is a delivery order contract awarded by the Department of Veterans Affairs (VA) to UroGen Pharma Inc., a for-profit pharmaceutical company, for the supply of JELMYTO kits. The contract has a ceiling value of $102,264.12 and is valid through September 30, 2025. The contract was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is structured as a firm fixed-price delivery order. No set-aside was used. UroGen Pharma has held multiple indefinite delivery vehicle...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $194,860.32 delivery order to Urogen Pharma Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The firm fixed price order is for the delivery of JELMYTO mitomycin and has an anticipated completion date of August 9, 2023. Placement on the Pharmaceuticals and Drugs FSS vehicle establishes pre-negotiated pricing terms for ordering agencies like the VA to...
The Department of Veterans Affairs Veterans Health Administration awarded a $97,430 firm fixed price delivery order against GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB) to Urogen Pharma Inc. to provide JELMYTO, a treatment for low-grade upper tract urothelial cancer. The contract has a period of performance of June 22, 2023 through June 23, 2023 and will be performed in La Vergne, Tennessee. GSA Schedule FSS-61-IB, administered by the VA-VHA, provides pharmaceuticals and drugs to support...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a delivery order to Otsuka America Pharmaceutical Inc., a for-profit manufacturer of pharmaceuticals, for the supply of the drug TOLVAPTAN (JYNARQUE) for the treatment of kidney disorders. The $102,766.58 firm-fixed price order was issued under Otsuka's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), without any set-aside designations. Otsuka has held multiple VA delivery orders...
The U.S. Department of Veterans Affairs (VA) awarded a firm-fixed price delivery order contract to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, for the supply of JYNARQUE 90MG-30MG medication. The contract, which is not designated as a set-aside, has a ceiling value of $13,168.39 and is expected to be completed by June 11, 2025. This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and supports the VA's mission of...
This federal contract award is for the delivery of the pharmaceutical drug Jynarque (tolvaptan) to the U.S. Department of Veterans Affairs (VA) by Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer. The contract has an award value of $12,559.90 and a period of performance through August 6, 2024. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract was issued under Otsuka's Federal Supply Schedule (FSS) contract with the...
This is a federal delivery order awarded by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The $13,168.39 firm-fixed price contract is for the drug Jynarque (tolvaptan) in the 90mg/30mg dosage. This delivery order is part of a larger $15 million Blanket Purchase Agreement (BPA) specifically for Jynarque, as well as a $396 million Federal Supply Schedule contract for pharmaceuticals and hematology-related...
The U.S. Department of Veterans Affairs (VA) awarded a delivery order contract to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, for the supply of the drug Jynarque (tolvaptan) in 90mg/30mg dosages. The contract, valued at $12,559.90, has an ultimate completion date of September 30, 2024. Otsuka America Pharmaceutical holds two significant Indefinite Delivery Vehicle (IDV) contracts with the VA: a $15 million Blanket Purchase Agreement (BPA) specifically for the...